About 1 in 5 people worldwide develop cancer at some point in their lives. In the United States specifically, roughly 18.6 million people are currently living with a cancer diagnosis, which represents about 5.4% of the population. Those two numbers capture different things: lifetime risk tells you the odds of ever getting cancer, while prevalence tells you how many people have it right now.
Lifetime Risk vs. Current Prevalence
The distinction matters because many people who develop cancer are treated successfully and eventually considered cancer-free. The World Health Organization estimates that about 1 in 5 people will develop cancer during their lifetime. Death rates are lower: approximately 1 in 9 men and 1 in 12 women die from the disease. The gap between those numbers reflects the millions of people who survive.
In the U.S., the National Cancer Institute estimates 18.6 million cancer survivors as of 2025, about 5.4% of the total population. That figure includes everyone from people currently in treatment to those who finished treatment decades ago. It’s the broadest possible count of Americans whose lives have been touched by a cancer diagnosis.
How Age Changes the Numbers
Cancer is overwhelmingly a disease of aging. The median age at diagnosis is 67, meaning half of all cancers are found in people older than that. Incidence rates climb steeply with each decade of life: fewer than 26 cases per 100,000 people in age groups under 20, roughly 350 per 100,000 among those aged 45 to 49, and more than 1,000 per 100,000 in age groups 60 and older.
Children and adolescents under 20 account for just 1% of all cancer diagnoses. Globally, about 400,000 children and adolescents develop cancer each year, according to the WHO. While childhood cancers are serious and often aggressive, they are statistically rare compared to cancers diagnosed later in life.
The Most Common Types
A handful of cancer types make up a large share of all new diagnoses. In the U.S., estimated new cases for 2025 give a sense of scale:
- Breast cancer: about 317,000 new cases
- Prostate cancer: about 314,000 new cases
- Lung cancer: about 227,000 new cases
- Colorectal cancer: about 154,000 new cases
Together, these four types account for well over a million new diagnoses annually in the U.S. alone. Breast and prostate cancers top the list partly because screening catches many cases early, including slow-growing tumors that might never cause symptoms.
Differences Between Countries
Where you live significantly affects both your likelihood of being diagnosed and your chances of surviving. High-income countries tend to report higher incidence rates, partly because they have better screening programs that detect cancers that might go undiagnosed elsewhere. But survival rates are also substantially better in wealthier nations.
One way researchers measure this is the mortality-to-incidence ratio (MIR), which captures how many people diagnosed with cancer end up dying from it. In high-income countries, that ratio averages 0.47, meaning roughly half of diagnosed patients die from the disease. In middle- and low-income countries, the ratio jumps to 0.64. The difference comes down to resources: access to early detection, surgical care, chemotherapy, and radiation. In wealthier countries, higher spending on healthcare and more medical infrastructure directly correlate with better outcomes. In lower-income countries, the overall quality of the healthcare system matters more than any single spending metric.
Global Cases Are Rising
The global cancer burden is growing quickly. An estimated 20 million new cancer cases were diagnosed worldwide in 2022. The WHO projects that number will reach over 35 million by 2050, a 77% increase. Population aging is the biggest driver. As life expectancy rises in countries around the world, more people reach the ages where cancer becomes common. Other contributing factors include rising obesity rates, increasing alcohol consumption, and air pollution.
That projection doesn’t necessarily mean your individual risk is climbing dramatically. Much of the increase reflects more people living long enough to develop cancer and more countries gaining the diagnostic capacity to detect it. Still, the raw numbers mean healthcare systems everywhere will need to handle significantly more cancer patients in the coming decades.